Here, we tested a novel ALK inhibitor entrectinib (RXDX-101) (Ignyta, San Diego) for its capacity to abrogate growth of NB cell lines with different status of ALK gene (wild type, mutated or amplified) in vitro. The gene discussed is ALK; the disease is neuroblastoma.